Poland· PL-100537690
Xefo Rapid
A lornoxicam product containing lornoxicamum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lornoxicam is registered in 5 of 19 countries.
Countries holding a registration under ATC M01AC05 (lornoxicam), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Lornoxicam · ATC M01AC05
5 / 19 countries
- Denmark
- Finlandprice
- Japan
- Polandprice
- United Kingdom
Price per daily dose
What a daily dose of lornoxicam costs, country by country.
Normalised to the WHO defined daily dose (12 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lornoxicam · price per daily dose (12 mg)
USD · FX 28 Sept 2026
- ES Spain$0.39
The record
At a glance
URPL (Poland)- Active substance
- Lornoxicamum
- Manufacturer
- InPharm Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- M01AC05
- ATC class
- Lornoxicam
- Defined daily dose
- 12 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 5
- gtin05909991599997
- gtin05909991600006
- gtin05909991600013
- gtin05909991600020
- gtin05909991600037
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for lornoxicam.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lornoxicam · interactions on record
82 records
82 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Lornoxicam in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainACABEL 8 mg COMPRIMIDOS RECUBIERTOS CON PELICULAGrünenthal Pharma S.A.
- FinlandXefoNycomed Oy
- United KingdomLornoxicam 8mg tabletsSpecial Order
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- Austria · Xefo, Xefo Rapid
- Bulgaria · Ксефо Рапид, Лорнадo
- Denmark · Lornoxicam Takeda, Xefo
- Spain · Lornoxicam Rapid Meiji
- Greece · Xefo, Xefo Rapid
- Hungary · Xefo, Xefo Rapid
- Lithuania · Xefo
- Latvia · Xefo
- Romania · Lornoxicam Rompharm, Xefo Rapid
- Slovakia · Xefo, Xefo Rapid
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f238f2f2-6d29-46c9-b049-c08d890e4878 GET /v1/drugs/f238f2f2-6d29-46c9-b049-c08d890e4878?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "8 mg",
"packaging": "05909991599997 ¦ Rp ¦ 166901\n10 tabl.\n05909991600006 ¦ Rp ¦ 166902\n20 tabl.\n05909991600013 ¦ Rp ¦ 166903\n30 tabl.\n05909991600020 ¦ Rp ¦ 166904\n50 tabl.\n05909991600037 ¦ Rp ¦ 166905\n100 tabl.",
"substance": "Lornoxicamum 8 mg",
"common_name": "Lornoxicamum",
"pl_product_id": "100537690",
"pozwolenie_nr": "163/26",
"auth_procedure": "IR",
"authorisation_validity": "2031-04-28"
}See everything about lornoxicam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.